Fused Bicyclic Pyrazoles for Rapid RBP4 Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments for metabolic diseases and disorders associated with retinol-binding protein 4 (RBP4), such as obesity, diabetes, and liver diseases like non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Innovation Solution
Administration of heterocyclic derivative compounds, including specific fused bicyclic pyrazoles, in therapeutically effective amounts to reduce RBP4 levels in subjects, thereby treating metabolic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for metabolic diseases are used, then disease management is attempted, but they fail to effectively reduce RBP4 levels and provide sufficient therapeutic benefit
Solution Approach 1:
The patent employs parameter changes by modifying molecular structure parameters of the compounds (Formula I with various substituents R1-R6, ring structures A and B) to optimize RBP4 binding affinity and therapeutic effectiveness across different metabolic diseases including obesity, diabetes, and liver diseases
Solution Approach 2:
The patent achieves universality by designing compounds with core structural features (Formula I) that can treat multiple metabolic diseases simultaneously - obesity, type 2 diabetes, and liver diseases (NAFLD, NASH) - through the common mechanism of RBP4 level reduction, making a single compound class applicable to diverse metabolic conditions
2Speed
If RBP4 levels are reduced by at least 50% within 24 hours, then therapeutic benefits are achieved, but this requires high potency compounds with specific structural features
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: core pyrazole ring structure, substituent groups (R1-R6), and ring systems (A and B), allowing independent optimization of each segment to achieve both rapid RBP4 reduction and manageable structural complexity
Solution Approach 2:
The patent uses local quality by assigning specific functional properties to different parts of the molecule - certain substituents (R1-R6) enhance binding affinity for rapid RBP4 reduction, while ring structures (A and B) provide structural stability, creating locally optimized regions that collectively achieve the desired therapeutic effect
Data Source
AI summary
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.